Frontlight ResearchEarly access
CompletedPhase 2
Efficacy, Safety, Tolerability, and Biomarkers of Ibudilast (MN-166) in Patients Hospitalized With COVID-19 at Risk for ARDS
Key facts
- Who runs it
- MediciNova
- Where
- Denver and New Haven, United StatesSee the 2 sites
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 34 people enrolled
- Started
- 11 Jan 2021
- Ended
- 7 Aug 2024
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Ibudilast
- Placebo
- Record updated
- 30 October 2024
Who can take part
- Age
- 18 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- SARS-CoV-2 infection confirmed with WHO criteria (including a positive PCR of any specimen, e.g., blood, respiratory, stool, urine, or any other body fluid)
- Chest imaging (radiograph, computerized tomography (CT) scan or lung ultrasound) with abnormalities consistent with COVID-19 pneumonia
- Oxygen saturation (SpO2) ≤92% on room air (RA), respiratory rate ≥24 breaths per min on RA, and/or requirement for supplemental oxygen
- At least 1 risk factor which may put patient at higher risk for more severe illness from COVID-19: Age > 65, underlying serious heart disease, chronic lung disease, moderate to severe asthma, body mass index of ≥40, or diabetes
Who cannot take part
- Known or suspected immunosuppression with immunosuppressant medications or chemotherapeutic agents
- Patient is receiving dialysis treatment
- Suspected active bacterial, fungal, viral, or other cause of respiratory failure other than COVID-19
- On a home ventilator support or continuous domiciliary oxygen therapy for baseline lung disease
- Active tuberculosis infection
- Subject is already intubated and on ventilator support
Where in United States
- Denver Health and Hospital AuthorityDenver, United States
- Yale University School Of MedicineNew Haven, United States
About the trial
What the trial wants to find out
The goal of this study is to evaluate the effects of Ibudilast (MN-166) versus placebo in hospitalized patients infected with COVID-19 at risk for developing acute respiratory distress syndrome (ARDS) receiving standard of care (including anticoagulation therapy) by measuring the following outcomes: 1) the need for oxygen therapy at Days 7, 14, and 28, 2) clinical status as measured by the National Institute of Allergy and Infectious Diseases (NIAID) ordinal scale at Days 7, 14, and 28, and 3) safety (as measured by incidence of adverse events and clinical laboratory findings) and tolerability of Ibudilast.
The 2 groups in the trial
- Active Treatment GroupTreatment being tested
Treatment: Ibudilast
- Placebo Treatment GroupPlacebo, for comparison
Treatment: Placebo
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, Tolerability, Biomarkers and Pharmacokinetics of Ibudilast (MN-166) in COVID-19 Subjects at Risk for Developing Acute Respiratory Distress Syndrome
- Publications
- Record updated
- 30 October 2024